X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LBS-008 (tinlarebant) is a novel Retinol-binding protein 4 inhibitor, small molecule drug candidate. It is being evaluated for the treatment of Stargardt Disease.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
LBS-008 (tinlarebant) is a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced Dry AMD.
Lead Product(s): Tinlarebant
Therapeutic Area: Ophthalmology Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
LBS-008 (tinlarebant) is an orally administered tablet, once daily retinol binding protein 4 (RBP4) antagonist designed to lower levels of ocular vitamin-A based toxins implicated in STGD1.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
Belite Bio intends to use the net proceeds of the offering for clinical trials and further clinical development of LBS-008 (tinlarebant), a novel oral therapy intended as an early intervention to prevent the accumulation of vitamin A-based toxins (bisretinoids).
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SVB Securities LLC
Deal Size: $30 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 30, 2023
Details:
LBS-008 (tinlarebant) is a novel oral therapy intended as an early intervention to prevent the accumulation of vitamin A-based toxins (bisretinoids) that cause STGD1 and contribute to pathogenesis in Dry AMD.
Lead Product(s): Tinlarebant
Therapeutic Area: Ophthalmology Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2022
Details:
LBS-008 (aka Tinlarebant), is a novel oral therapy that prevents the buildup of toxins in the eye was safe and well tolerated in adolescent Stargardt Disease (STGD1) subjects at 12-month time point.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2022
Details:
Preliminary data from the Phase 2 trial of LBS-008 (tinlarebant) at the first 6-month interval shows that 8 of the 13 patients (or 61.5%) recorded a gain in best-corrected visual acuity (BCVA) in at least one eye, including 2 patients who recorded a BCVA gain in both eyes.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
LBS-008 (tinlarebant) is orally-available, small molecule retinol binding protein 4 antagonist that selectively reduces delivery of vitamin A (retinol) to eye, leading to a reduction of toxic vitamin A byproducts that have been implicated in the onset and progression of STGD1.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 22, 2022
Details:
LBS-008 (tinlarebant) is small molecule RBP4 antagonist that selectively reduces the delivery of vitamin A (retinol) to eye leading to a reduction of toxic vitamin A byproducts (bisretinoids) that have been implicated in onset and progression of STGD1.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
LBS-008 (tinlarebant) is a novel oral therapy that prevents the buildup of toxins in the eye that cause STGD1 and contribute to dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye.
Lead Product(s): Tinlarebant
Therapeutic Area: Genetic Disease Product Name: LBS-008
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
